NEW YORK, Oct. 14, 2016 -- LifeSci Advisors LLC, (the "Company" or "LifeSci") the leading international investor relations and corporate communications firm dedicated to the life sciences sector, today announced the appointment of Frank Gaul as Director of Corporate Access. Based in Boston, Mr. Gaul will enhance and help manage LifeSci’s corporate access capabilities.
Mr. Gaul has 20 years of experience in equity sales, including 14 years in institutional healthcare equity sales. Most recently, he was in Equity Research Sales at Vertical Research Group, an independent equity research boutique, and previously served in similar roles at Adams, Harkness & Hill, Canaccord Adams and Leerink Swann. During his career, Mr. Gaul has established and developed relationships with many top-tier buy-side investors and sell-side analysts and bankers.
Throughout his career, Mr. Gaul has managed numerous deal and non-deal roadshows in all major financial markets in the United States. He also has healthcare industry experience, having held senior sales roles at Healthcare Services Management Inc. and Epocrates (acquired by athenahealth). He received a Bachelor of Arts degree in English and Economics from Wheaton College.
Over the last year, LifeSci has been investing significantly in better serving its clients and relevant investment communities, not only in the U.S., but also in Europe and Israel, having recently established offices in Israel, UK and Switzerland. In the process, the firm has added managing directors, Niki Dilger (UK), Moran Meir-Beres (Israel) and Chris Maggos (Switzerland).
"I am very pleased to welcome Frank to the team,” said Michael Rice, President and Co-Founder of LifeSci Advisors. "He joins a talented group of professionals and strengthens the overall reach and execution capability of our corporate access team. Since the founding of LifeSci, our business model has been to differentiate ourselves by hiring seasoned Wall Street executives who have established strong track records in institutional equity sales and corporate finance, can leverage their relationships within the investment community and possess an in-depth understanding of the healthcare industry. Frank fits that profile perfectly.”
“We now have what I believe to be the largest and most experienced corporate access team in healthcare IR,” continued Mr. Rice. “As a result, we can service our corporate clients globally by making the most appropriate investor introductions and orchestrating the highest quality roadshows.”
“I am thrilled to be joining LifeSci Advisors at this exciting period of growth for the firm,” said Mr. Gaul. “LifeSci’s service offering is unique among healthcare-focused investor relations firms and it has quickly established itself as an industry leader.”
LifeSci Advisors, LLC (www.lifesciadvisors.com) is a unique investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. With a local presence in New York, Boston, Chicago, Philadelphia, London, Geneva and Tel Aviv, the firm provides the highest quality service for its clients through its deep sector specialization. Our roster of PhDs enables us to better understand our clients' R&D, regulatory, and commercial strategy, and our team of capital markets, investor relations, and public relations specialists help our clients effectively communicate to the marketplace. This combination of life sciences, capital markets, and investor relations competencies allows us to provide a valuable and highly differentiated service offering to our clients.
For further information, please contact: Michael Rice Founding Partner LifeSci Advisors, LLC (646) 597-6979


7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Italy Fines Apple €98.6 Million Over App Store Dominance
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 



